Fluorouracil (5-FU)

DRUG12 trials

Sponsors

M.D. Anderson Cancer Center, University of Utah, Oncolytics Biotech, Symphogen A/S, Yun-fei Xia

Conditions

Advanced Solid TumorBiliary Tract CancerCancerColorectal CancerEsophageal Squamous Cell Carcinoma (ESCC)Gastric CancerGastroesophageal Junction (GEJ) AdenocarcinomaKRAS Mutant Metastatic Colorectal Cancer

Phase 1

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

CompletedNCT01274624

Oncolytics BiotechKRAS Mutant Metastatic Colorectal Cancer

Start: 2010-12-31End: 2018-11-30Updated: 2018-12-19

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

RecruitingNCT06428409

Merck Sharp & Dohme LLCBiliary Tract Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2024-06-20End: 2029-10-16Target: 220Updated: 2026-01-22

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

TerminatedNCT06509906

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumor

Start: 2024-10-08End: 2025-12-02Updated: 2025-12-18

Phase 2

Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

CompletedNCT00004142

M.D. Anderson Cancer CenterColorectal Cancer, Metastatic Cancer

Start: 1998-08-05End: 2003-12-09Updated: 2018-10-26

Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma

TerminatedNCT00983541

University of UtahCancer

Start: 2009-09-30End: 2012-03-31Updated: 2015-08-19

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

CompletedNCT02083653

Symphogen A/SMetastatic Colorectal Cancer

Start: 2014-03-06End: 2017-04-26Updated: 2019-04-16

A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC

Yun-fei XiaNasopharyngeal Carcinoma

Start: 2015-07-31End: 2020-12-31Target: 328Updated: 2017-12-22

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

RecruitingNCT04379596

AstraZenecaGastric Cancer

Start: 2020-06-03End: 2027-06-01Target: 450Updated: 2026-02-23

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

RecruitingNCT07018570

National Cancer Center Hospital EastGastroesophageal Junction (GEJ) Adenocarcinoma

Start: 2025-07-24End: 2031-06-30Target: 26Updated: 2025-08-26

Phase 3

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

CompletedNCT03783442

BeiGeneEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2018-12-11End: 2024-08-22Updated: 2025-07-29

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Active, not recruitingNCT04241185

Merck Sharp & Dohme LLCUrinary Bladder Neoplasms

Start: 2020-05-19End: 2031-11-01Target: 520Updated: 2024-11-25

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

RecruitingNCT06733038

Gruppo Oncologico del Nord-OvestColorectal Cancer

Start: 2024-11-15End: 2029-04-01Target: 238Updated: 2025-12-08

Related Papers

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up.

2026-04-01

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer

ESMO Gastrointestinal Oncology2026-01-20

First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5.

Journal of Clinical Oncology2026-01-10

An open label phase 2 study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (EPOC2301).

Journal of Clinical Oncology2026-01-10

Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line treatment for locally advanced (LA), unresectable esophageal squamous cell carcinoma (ESCC): PD-L1 tumor area positivity (TAP) score ≥1% subgroup analysis of RATIONALE-306.

Journal of Clinical Oncology2026-01-10

Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab.

2025-05-135 citations

Abstract 1171: M9466 (HRS-1167): A highly potent and selective PARP1 inhibitor with DNA trapping activity, monotherapy antitumor activity and synergistic potential with DDR inhibitors and chemotherapies

Cancer Research2025-04-21

First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

Advances in Therapy2025-03-135 citations

Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).

Journal of Clinical Oncology2025-01-274 citations

Phase 1/2 study of the trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy or combination therapy in gastrointestinal cancers: LIGHTBEAM-02A.

Journal of Clinical Oncology2025-01-27

First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.

Journal of Clinical Oncology2025-01-27

Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.

Journal of Clinical Oncology2025-01-27

Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.

Journal of Clinical Oncology2024-06-011 citations

Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

Journal of Clinical Oncology2024-06-01

Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology2024-01-2910 citations

Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03).

Journal of Clinical Oncology2024-01-2010 citations

Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer Patients

Diseases2023-10-167 citations

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.

2023-04-17193 citations

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.

2023-03-156 citations

Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.

Journal of Clinical Oncology2023-01-24

13 more papers not shown